Asia Pacific Anti-Infective Agents Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- anti infective agents market
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the anti infective agents market
Asia Pacific anti-infective agents market highlights
- The Asia Pacific anti-infective agents market generated a revenue of USD 33,967.4 million in 2025.
- The market is expected to grow at a CAGR of 3.7% from 2026 to 2033.
- In terms of segment, antibacterials was the largest revenue generating type in 2025.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 33,967.4 million |
| Market revenue in 2033 | USD 44,829.0 million |
| Growth rate | 3.7% (CAGR from 2026 to 2033) |
| Largest segment | Antibacterials |
| Fastest growing segment | Antifungals |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 25.4% of the global anti-infective agents market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 44,829.0 million by 2033.
Collaborative efforts and strategic partnerships are also on the rise, exemplified by recent license agreements that grant development and commercialization rights to companies specializing in antiinfective research.
In April 2023, Asahi Kasei Pharma received approval to produce and market Cresemba Capsule 40 mg in Japan as a new formulation for treating invasive fungal infections. Regulatory bodies in the region are increasingly streamlining approval processes for innovative treatments, further enhancing the market landscape.
No credit card required*
Publish Date: Jun 25, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti Infective Agents Market
Anti Infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Mankind Pharma | View profile | 10001+ | New Delhi, Delhi, India, Asia | www.mankindpharma.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
Asia Pacific anti infective agents market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antibacterials was the largest segment with a revenue share of 66.28% in 2025.
Horizon Databook has segmented the Asia Pacific anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
Collaborative efforts and strategic partnerships are also on the rise, exemplified by recent license agreements that grant development and commercialization rights to companies specializing in antiinfective research.
In April 2023, Asahi Kasei Pharma received approval to produce and market Cresemba Capsule 40 mg in Japan as a new formulation for treating invasive fungal infections. Regulatory bodies in the region are increasingly streamlining approval processes for innovative treatments, further enhancing the market landscape.
- Asia Pacific Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antibacterials
- Antivirals
- Antifungals
- Asia Pacific Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Topical
- Others
- Asia Pacific Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to anti infective agents market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
- Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific anti infective agents market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Anti-Infective Agents Market, 2021-2033 (US$M)
Asia Pacific Type - Anti-infective Agents Market Statistics, 2025 - 2033 (US$M)
